Magdalena Bürkle

Ms. Magdalena Bürkle

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in The ISME Journal
Verified
Journal Article
Open access
MBMagdalena Bürkle
Magdalena Bürkle
IKImke Korf
Imke Korf
ALAnne Lippegaus
Anne Lippegaus
SKSebastian Krautwurst
Sebastian Krautwurst
CRChristine Rohde
Christine Rohde
GKGopinath Krishnamoorthy
Gopinath Krishnamoorthy
Virulent bacteriophages (or phages) are viruses that specifically infect and lyse a bacterial host. When multiple phages co-infect a bacterial host, the extent of lysis and dynamics of bacteria–phage and phage–phage interactions are expected to vary. The objective of this study is to identify the factors influencing the interaction of two virulent phages with different Pseudomonas aeruginosa growth states (planktonic, an infected epithelial cell line, and biofilm) by measuring the bacterial time-kill and individual phage replication kinetics. A single administration of phages effectively reduced P. aeruginosa viability in planktonic conditions and infected human lung cell cultures, but phage-resistant variants subsequently emerged. In static biofilms, the phage combination displayed initial inhibition of biofilm dispersal, but sustained control was achieved only by combining phages and the meropenem antibiotic. In contrast, adherent biofilms showed tolerance to phage and/or meropenem, suggesting a spatio-temporal variation in the phage–bacterial interaction. The kinetics of adsorption of each phage to P. aeruginosa during single or co-administration were comparable. However, the phage with the shorter lysis time depleted bacterial resources early and selected a specific nucleotide polymorphism that conferred a competitive disadvantage and cross-resistance to the second phage. The extent and strength of this phage–phage competition and genetic loci conferring phage resistance are, however, P. aeruginosa genotype-dependent. Nevertheless, adding phages sequentially resulted in their unimpeded replication with no significant increase in bacterial host lysis. These results highlight the interrelatedness of phage–phage competition, phage resistance, and specific bacterial growth state (planktonic/biofilm) in shaping the interplay among P. aeruginosa and virulent phages.

15 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CWChantal Viola Weißfuß
Chantal Viola Weißfuß
JLJingjing Li
Jingjing Li
UBUlrike Behrendt
Ulrike Behrendt
KHKaren Hoffmann
Karen Hoffmann
MBMagdalena Bürkle
Magdalena Bürkle
GNGeraldine Nouailles
Geraldine Nouailles
Bacterial multidrug resistance poses an urgent challenge for the treatment of critically ill patients developing ventilator-associated pneumonia (VAP). Phage therapy, a potential alternative when conventional antibiotics fail, has been unsuccessful in first clinical trials when used alone. Whether combining antibiotics with phages may enhance effectiveness remains to be tested in experimental models. Here, we use a murine model of Pseudomonas-induced VAP to compare the efficacy of adjunctive phage cocktail for antibiotic therapy to either meropenem or phages alone. Combined treatment in murine VAP results in faster clinical improvement and prevents lung epithelial cell damage. Using human primary epithelial cells to dissect these synergistic effects, we find that adjunctive phage therapy reduces the minimum effective concentration of meropenem and prevents resistance development against both treatments. These findings suggest adjunctive phage therapy represents a promising treatment for MDR-induced VAP, enhancing the effectiveness of both antibiotics and phages while reducing adverse effects.

29 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CWChantal Viola Weißfuß
Chantal Viola Weißfuß
SWSandra-Maria Wienhold
Sandra-Maria Wienhold
MBMagdalena Bürkle
Magdalena Bürkle
BGBaptiste GABORIEAU
Baptiste GABORIEAU
JBJudith Bushe
Judith Bushe
GNGeraldine Nouailles
Geraldine Nouailles
Phage therapy of ventilator-associated pneumonia (VAP) is of great interest due to the rising incidence of multidrug-resistant bacterial pathogens. However, natural or therapy-induced immunity against therapeutic phages remains a potential concern. In this study, we investigated the innate and adaptive immune responses to two different phage cocktails targeting either Pseudomonas aeruginosa or Escherichia coli—two VAP-associated pathogens—in naïve mice without the confounding effects of a bacterial infection. Active or UV-inactivated phage cocktails or buffers were injected intraperitoneally daily for 7 days in C57BL/6J wild-type mice. Blood cell analysis, flow cytometry analysis, assessment of phage distribution and histopathological analysis of spleens were performed at 6 h, 10 days and 21 days after treatment start. Phages reached the lungs and although the phage cocktails were slightly immunogenic, phage injections were well tolerated without obvious adverse effects. No signs of activation of innate or adaptive immune cells were observed; however, both active phage cocktails elicited a minimal humoral response with secretion of phage-specific antibodies. Our findings show that even repetitive injections lead only to a minimal innate and adaptive immune response in naïve mice and suggest that systemic phage treatment is thus potentially suitable for treating bacterial lung infections.

26 September 2024 in Research Square
Verified
Preprint
Open access
PDF file
CWChantal Viola Weißfuß
Chantal Viola Weißfuß
JLJingjing Li
Jingjing Li
UBUlrike Behrendt
Ulrike Behrendt
KHKaren Hoffmann
Karen Hoffmann
MBMagdalena Bürkle
Magdalena Bürkle
GNGeraldine Nouailles
Geraldine Nouailles
Bacterial multidrug resistance poses an urgent challenge for the treatment of critically ill patients developing ventilator-associated pneumonia (VAP). Phage therapy, a potential alternative when conventional antibiotics fail, has been unsuccessful in first clinical trials when used alone. Whether combining antibiotics with phages may enhance effectiveness remains to be tested in experimental models. Here, we used a murine model of Pseudomonas aeruginosa-induced VAP to compare the efficacy of adjunctive phage cocktail for antibiotic therapy to either meropenem or the phage cocktail alone. Combined treatment led to faster recovery of VAP-mice and prevented lung epithelial cell damage. Using human primary epithelial cells to dissect these synergistic effects, we find that adjunctive phage therapy reduced the minimum effective concentration of meropenem and prevented resistance development against both treatments. These findings suggest adjunctive phage therapy represents a promising treatment for MDR-induced VAP, enhancing the effectiveness of both antibiotics and phages while reducing adverse effects.

13 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MBMagdalena Bürkle
Magdalena Bürkle
IKImke Korf
Imke Korf
ALAnne Lippegaus
Anne Lippegaus
SKSebastian Krautwurst
Sebastian Krautwurst
CRChristine Rohde
Christine Rohde
GKGopinath Krishnamoorthy
Gopinath Krishnamoorthy
Combined use of virulent bacteriophages (phages) and antibiotics reduces the severity of difficult-to-treat Pseudomonas aeruginosa infections in many patients. In vitro methods that attempt to reproduce more than one physiological state of the pathogens can provide a valuable assessment of antibacterials like phages. Here, by measuring bacterial killing kinetics and individual replication in different growth conditions, including biofilms and a human lung epithelial cell line, we elucidated factors influencing the efficacy of two virulent phages against P. aeruginosa PAO1. A single administration of phages effectively reduced the P. aeruginosa viability in planktonic conditions and infected human lung cell cultures, however, the emergence of phage-resistant variants occurred subsequently. In static biofilms, the phage combination displayed initial inhibition of biofilm dispersal, but sustained control was achieved only by combining phages and meropenem. In contrast, surface-attached biofilms exhibited tolerance to phage and/or meropenem, suggesting a spatiotemporal variation in the antibacterial effect. Moreover, the phage with the shorter lysis time lysed P. aeruginosa more rapidly and selected a specific nucleotide polymorphism that conferred a competitive disadvantage and cross-resistance to the second phage of the combination. The sequential addition of phages resulted in their unimpeded replication with no increase in bacteriolytic activity. These findings highlight biofilm developmental stages, phage-phage competition, and phage resistance as factors restricting the in vitro efficacy of a two-phage combination. Our findings provide a framework for selecting and optimizing phage combinations for enhanced efficacy against P. aeruginosa , a metabolically flexible pathogen that undergoes specific adaptation within the infected lung.